Teva Pharmaceutical Industries Ltd (TEVA.N)

TEVA.N on New York Stock Exchange

53.64USD
24 Oct 2014
Price Change (% chg)

$0.04 (+0.07%)
Prev Close
$53.60
Open
$53.57
Day's High
$54.15
Day's Low
$53.02
Volume
445,866
Avg. Vol
610,906
52-wk High
$55.70
52-wk Low
$36.26

TEVA.N

Chart for TEVA.N

About

Teva Pharmaceutical Industries Ltd (Teva) is an Israel-based pharmaceutical and drug company. It develops, produces and markets generic drugs in all treatment categories. The Company has a pharmaceutical business, whose principal products include Copaxone and Azilect. Teva’s active pharmaceutical ingredient (API) business... (more)

Overall

Beta: 0.64
Market Cap (Mil.): $51,749.04
Shares Outstanding (Mil.): 953.25
Dividend: 0.34
Yield (%): 2.54

Financials

  TEVA.N Industry Sector
P/E (TTM): 17.67 33.21 34.06
EPS (TTM): 3.04 -- --
ROI: 7.47 18.18 17.45
ROE: 11.47 18.85 18.26
Search Stocks

UPDATE 2-U.S. top court divided in battle over Teva MS drug patent

(Adds fresh details from oral argument, paragraphs 8-9, 11-12)

15 Oct 2014

U.S. Supreme Court justices divided over Teva patent battle

WASHINGTON, Oct 15 - The U.S. Supreme Court on Wednesday appeared closely divided as it weighed Teva Pharmaceutical Industries Ltd's high-profile fight with generic drug manufacturers over patent protections for Copaxone, its top-selling multiple sclerosis drug.

15 Oct 2014

U.S. top court hears Teva's multiple sclerosis drug patent fight

WASHINGTON - The U.S. Supreme Court on Wednesday is set to wade into Teva Pharmaceutical Industries Ltd's fight over patent protections for Copaxone, its top-selling multiple sclerosis drug, in one of the most important business cases of the justices' new term.

15 Oct 2014

U.S. top court hears Teva's multiple sclerosis drug patent fight

WASHINGTON, Oct 15 - The U.S. Supreme Court on Wednesday is set to wade into Teva Pharmaceutical Industries Ltd's fight over patent protections for Copaxone, its top-selling multiple sclerosis drug, in one of the most important business cases of the justices' new term.

15 Oct 2014

Actavis to buy Durata in a deal valued at about $675 million

- Generic drugmaker Actavis Plc said it would acquire Durata Therapeutics Inc in a deal valued at about $675 million to bolster its infectious disease portfolio.

06 Oct 2014

UPDATE 1-Actavis to buy Durata in a deal valued at about $675 mln

Oct 6 - Generic drugmaker Actavis Plc said it would acquire Durata Therapeutics Inc in a deal valued at about $675 million to bolster its infectious disease portfolio.

06 Oct 2014

Teva Pharm to halt R&D in cancer and women's health to cut costs

TEL AVIV - Teva Pharmaceutical Industries said it will stop research and development in areas such as oncology and women's health to cut costs, though it will maintain a commercial presence in these areas.

06 Oct 2014

Teva Pharm to halt R&D in cancer and women's health to cut costs

TEL AVIV, Oct 6 - Teva Pharmaceutical Industries said it will stop research and development in areas such as oncology and women's health to cut costs, though it will maintain a commercial presence in these areas.

06 Oct 2014

CORRECTED-BRIEF-Teva Pharmaceutical present new data on MS drug Copaxone

(Corrects company name in headline to Teva Pharmaceutical from Teva Pharmaceuticals. Also, removes incorrect reference to Copaxone as an experimental MS drug)

11 Sep 2014

UPDATE 2-AbbVie, Teva broke law in AndroGel "pay for delay" deal, U.S. says

WASHINGTON, Sept 8 - The U.S. Federal Trade Commission on Monday sued Drugmakers AbbVie Inc and Teva Pharmaceuticals Industries Ltd for allegedly illegally preventing generic versions of AndroGel, for men with low testosterone, from getting to market.

09 Sep 2014

Competitors

  Price Change
Novartis AG (NOVN.VX) CHF85.75 +0.35
Biogen Idec Inc (BIIB.OQ) $311.41 +4.70

Earnings vs. Estimates

Search Stocks